Kansas court pre­lim­i­nar­i­ly ap­proves Vi­a­tris' $264M EpiPen set­tle­ment

A fed­er­al court has signed off on a set­tle­ment that will see Vi­a­tris pay $264 mil­lion to re­solve claims that it con­spired with Pfiz­er to “mo­nop­o­lize the mar­ket” for life-sav­ing EpiPens.

Kansas Judge Daniel Crab­tree pre­lim­i­nar­i­ly agreed to the set­tle­ment on Fri­day, paving the way for a fi­nal ap­proval that won’t come un­til at least the sec­ond half of the year. A fair­ness hear­ing will take place on Ju­ly 6, ac­cord­ing to court doc­u­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER